NCT04583280: A reported trial by Janssen Research & Development, LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04583280 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (<28 Days of Age), Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 6, 2021 |
| Completion date | March 18, 2022 |
| Required reporting date | March 18, 2023, midnight |
| Actual reporting date | March 16, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |